Stockreport

Ra Pharmaceuticals Announces Completion of Dosing in Phase 2 Program of RA101495 SC in Paroxysmal Nocturnal Hemoglobinuria

RA PHARMACEUTICALS  (RARX) 
Last ra pharmaceuticals earnings: 11/7 07:00 am Check Earnings Report
US:NASDAQ Investor Relations: rapharma.com/news-investors
PDF 21 PNH patients completed 12-week dosing period and 16 continue on long-term extension study Dosing ongoing in Phase 2 study in generalized myast [Read more]